All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Legend Biotech, Pfizer, and Roche. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
BsAbs in community practice: CRS management
Do you know... Which of the following statements is true regarding CRS during bispecific antibody therapy in MM?
Teclistamab, talquetamab, elranatamab, and linvoseltamab are T-cell redirecting bispecific antibodies (BsAbs) used for the treatment of patients with relapsed/refractory multiple myeloma (RRMM).1 BsAbs offer response rates similar to chimeric antigen receptor (CAR) T-cell therapies, with the advantage of being off-the-shelf treatments.1 This allows for more flexible and timely treatment delivery compared with personalized cell therapies.1 Administering BsAbs in community practice may improve treatment access and patient outcomes.1
Cytokine release syndrome (CRS) is a systemic inflammatory response that occurs commonly during BsAb therapy and requires careful monitoring and management.1,2 Here, we highlight key strategies for risk mitigation and prophylaxis, recognition and monitoring, and management of CRS during BsAb treatment for RRMM in community practice.
This educational resource is independently supported by Pfizer. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
